PMID- 30439290
OWN - NLM
STAT- MEDLINE
DCOM- 20190118
LR  - 20190313
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 20
IP  - 1
DP  - 2019 Jan
TI  - Current therapeutical strategies for allergic rhinitis.
PG  - 83-89
LID - 10.1080/14656566.2018.1543401 [doi]
AB  - INTRODUCTION: Allergic rhinitis is a common condition with increasing prevalence 
      and is associated with several comorbid disorders such as bronchial asthma and 
      atopic dermatitis. If allergen avoidance is not possible, allergen-specific 
      immunotherapy is the only causal treatment option. AREAS COVERED: This review 
      focuses on current treatments and the future outlook for allergic rhinitis. 
      Pharmacotherapy includes mast cell stabilizers, antihistamines, 
      glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal 
      decongestants. Nasal GCSs are currently regarded as the most effective treatment 
      and are considered first-line therapy together with non-sedating antihistamines. 
      The new formulation MP29-02 combines the nasal GCS fluticasone propionate with 
      azelastine in one single spray and has achieved greater improvements than those 
      under monotherapy with modern GCSs or antihistamines. Furthermore, this review 
      discusses allergen immunotherapy alone and in combination with modern monoclonal 
      antibodies. EXPERT OPINION: Despite the variety of medications for allergic 
      rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to 
      more specific ones like histamine receptor or leukotriene blockers, to causal 
      therapy like immunotherapy, many patients still experience treatment failures or 
      unsatisfactory results. The ultimate goal may be to endotype every downstream 
      pathway separately in order to offer patients individualized, targeted therapy 
      with specific antibodies against the respective pathway.
FAU - Klimek, Ludger
AU  - Klimek L
AD  - a Center for Rhinology and Allergology , Wiesbaden , Germany.
FAU - Sperl, Annette
AU  - Sperl A
AD  - a Center for Rhinology and Allergology , Wiesbaden , Germany.
FAU - Becker, Sven
AU  - Becker S
AD  - b Department of Otorhinolaryngology , Mainz University Hospital , Mainz , 
      Germany.
FAU - Mosges, Ralph
AU  - Mosges R
AD  - c CRI - Clinical Research International Ltd ., Cologne , Germany.
FAU - Tomazic, Peter Valentin
AU  - Tomazic PV
AD  - d Department of General Otorhinolaryngology , Medical University of Graz , Graz , 
      Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181115
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Histamine Antagonists)
SB  - IM
MH  - Desensitization, Immunologic/*methods
MH  - Histamine Antagonists/pharmacology/*therapeutic use
MH  - Humans
MH  - Rhinitis, Allergic/*drug therapy/pathology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - allergen immunotherapy
OT  - antihistamines
OT  - nasal glucocorticosteroids
EDAT- 2018/11/16 06:00
MHDA- 2019/01/19 06:00
CRDT- 2018/11/16 06:00
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2019/01/19 06:00 [medline]
PHST- 2018/11/16 06:00 [entrez]
AID - 10.1080/14656566.2018.1543401 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2019 Jan;20(1):83-89. doi: 
      10.1080/14656566.2018.1543401. Epub 2018 Nov 15.